Abstract
Introduction
Over 24 million people worldwide suffer from some form of dementia with 4.6 million new diagnoses made every year and it is estimated that by 2040, 80 million people will be demented [1] . Alzheimer's disease (AD) is the most common neurodegenerative disorder and is responsible for approximately 60% of dementia cases [1] . Short-term memory loss and visual-spatial confusion are one of the earliest clinical manifestations in AD. As the disease progresses, memory loss becomes more severe and patients are unable to recognize familiar objects or persons. Eventually, decline in other cognitive domains manifests, including deficits in attention, language and spatial orientation and patients will not be able to maintain personal independence [2] [3] [4] [5] . [6] . Amyloid plaques are mainly formed by a small peptide called amyloid-␤ (A␤) [7, 8] , which can also accumulate intraneuronally [9] , whereas NFTs are formed by hyperphosphorylated tau [10] [11] [12] [13] .
Pathologically, the AD brain is characterized by prominent atrophy and by a profound loss of neurons and synapses, which is restricted to specific brain regions critical for learning and memory, including the temporal and parietal lobes, the frontal cortex and the cingulate gyrus. In addition to neuronal loss and atrophy, the AD brain has two main lesions, extracellular amyloid plaques and intraneuronal neurofibrillary tangles (NFTs)
A␤ is generated by the sequential cleavage of a larger precursor, the amyloid precursor protein (APP), which is encoded by a gene located on chromosome 21 [14] . APP can be processed by a nonamyloidogenic pathway or an amyloidogenic pathway. In the non-amyloidogenic pathways, which is the most common, APP is cleaved by the ␣-secretase enzymes, which cut APP in the middle of the A␤ sequence, therefore precluding the formation of A␤ [15] . In the non-amyloidogenic pathway APP is cleaved by BACE1 [16] [17] [18] [13, 31, 32] . Notably, the ratio of three to four repeats is equal in the adult brain; however, only the four-repeat isoforms are present in the fetal brain [33, 34] [35] . Importantly, there is direct evidence that tau phosphorylation inversely regulates its ability to bind to microtubules [36] . The phosphorylation state of tau is controlled by the activity of several kinases and phosphatases [37] [38] [39] . In AD and other tauopathies, tau is abnormally hyperphosphorylated therefore there is an increase in total levels of unbound tau that aggregates to form straight and paired helical filaments that form NFTs [36, 40] . Although evidence showed a correlation between NFTs and the memory decline in AD [41, 42] [52, 53] . Proteins tagged with chains of four or more ubiquitins are recognized by the 26S proteasome for degradation [52] [53] [54] . It is the E3 ligase that confers specificity to the process by selectively binding to a protein target. Ubiquitin monomers are liberated after proteasome degradation or are actively removed by the ubiquitin carboxyl-terminal hydrolases [55] . [59] . Fig. 1) [60] [61] [62] [63] [64] . It has also been shown that these structures contain ubiquitin-B mutant protein (UBB+1), a mutant ubiquitin carrying a 19-amino acid C-terminal extension generated by a transcriptional dinucleotide deletion [65] . Notably, UBB+1 has been shown to block ubiquitin-dependent proteolysis in neuronal cells [66] , to cause neuritic beading of mitochondria in associating with neuronal differentiation [67] and it has been suggested to be a mediator of A␤-induced neurotoxicity [68] .
Biology of the UPS

Structure of the proteasome
The involvement of the UPS in AD pathogenesis
Growing evidence suggest that alterations in the UPS function may be involved in AD pathogenesis. This view is supported by evidence showing that in AD brains ubiquitin accumulates in both plaques and tangles (
The AD brain is also characterized by the accumulation of oxidized proteins [69, 70] , which may further exacerbate the decrease in proteasome activity [71] . [72, 73] . Finally, changes in proteasome subunit composition have been reported in the AD brain [74] . Taken [75] .
Particularly intriguing is the finding that the ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), an enzyme that hydrolyses ubiquitin from poly ubiquitinated proteins to liberate ubiquitin monomers, is oxidized in AD and is down-regulated in the specific brain regions of early AD cases
Direct evidence of altered proteasome activity in AD brains has been reported [76, 77] [77] .
The interaction between A␤ and the proteasome
Growing evidence supports an interaction between A␤ and the proteasome system. In particular, early in vitro work using biochemical and scanning transmission electron microscopy experiments showed that A␤40 directly binds to the inside of the proteasome along the peptide channel and selectively inhibits the chymotrypsin-like activity of the 20S proteasome [78, 79] . More recent evidence shows that A␤42 also impairs proteasome activity [80, 81] . In particular it has been shown that A␤42 can inhibit proteasome function at the same extent as a known proteasome inhibitor [81] [82] . [83] . [81] . Similarly, there was ~50% reduction in proteasome activity in primary neurons isolated from APP transgenic mice compared to neurons isolated from wild-type mice [84] . Moreover, a near complete normalization in proteasome activity to wild-type levels was obtained when APP mutant neurons were treated with a ␥-secretase inhibitor [84] , strongly suggesting a direct involvement of A␤ in the reduction of proteasome function. Using a transgenic animal model (3ϫTg-AD) that develops both plaques and tangles in an age-dependent manner [85] , we showed that proteasome activity was significantly decreased in the brains of 6-and 9-month old 3ϫTg-AD mice but not in the brains of 12-month old mice [82] . These agedependent changes in proteasome activity in the 3ϫTg-AD mice correlate with the levels of intraneuronal A␤, which are higher in 6-and 9-month old mice compared to 12-month old mice [86, 87] . The proteasome deficits were rescued by A␤ immunotherapy [82] [80] . Consistent with these results, it has been shown that in a cell-free assay, the 20S proteasome degrades both A␤40 and A␤42 [82] . Moreover, we showed a striking increase in intracellular A␤40 and A␤42 in N2A cells treated with a proteasome inhibitor [82] . To determine if A␤ is degraded by the proteasome in vivo, we injected a proteasome inhibitor into the cerebral ventricle of 4-month old 3ϫTg-AD mice and measured A␤ levels 72 hrs later. Consistent with the in vitro data, these experiments showed that proteasome inhibition resulted in a significant increase in intraneuronal A␤ levels [82] . Taken together these data suggest that in addition to being degraded by specific proteases (e.g. IDE, NEP and ECE), A␤ is also degraded by the proteasome. Considering the well established decrease in proteasome function during aging [92, 93] , and the data reported above, it is tempting to speculate that the age-dependent proteasome dysfunction may participate to the accumulation of A␤ in AD brains. Further supporting this idea, it has been shown that both PS1 and PS2 are degraded by the proteasome [94] , thus a decrease in proteasome activity would likely increase ␥-secretase activity and A␤ production.
Particularly interesting is the finding that A␤ toxicity can be mediated by its interaction with the proteasome. Analysis of gene expression profile of rat primary cortical neurons incubated with aggregated A␤ further supported a link between A␤ and the UPS [68]. In this work, the authors identify an ubiquitin-conjugating enzyme, E2-25K/Hip2 as a mediator of A␤ neurotoxicity [68]. Along these lines, it has been shown that the A␤-induced synaptic dysfunction can be rescued by increasing expression of UCH-L1
Work in transgenic animal models of AD also supports a relationship between A␤ accumulation and UPS function. Towards this end, Oh and colleagues showed an inverse relationship between A␤ accumulation and proteasome function in the brains of mice overexpressing APP, suggesting the possibility that A␤42 accumulation may be responsible for an agedependent decrease in proteasome function detected in the brains of these mice
A major unresolved question is how A␤ physically interacts with the proteasome. Proteasomes are found in the plasma and nucleus but are also associated with plasma and internal membranes [95] . In addition, a study using immuno-EM showed that the 20S subunit of the proteasome was also present in the outer membranes and inner vesicle of the multivesicular bodies [84] . Considering that A␤ is produced in the membranes [9] where the presence of the proteasome has been reported, it is possible that A␤-proteasome interaction may occur there and not in the cytoplasm. At this point, this is just a possibility and further studies are necessary to clarify where A␤ and the proteasome interact. [76] . To further support this view, they showed, in vitro, that tau aggregates isolated from human AD brains can inhibit the proteasome, whereas nonaggregated tau isolated from AD brains or normal tau isolated from control brains was not able to do so [76] . These data show that different aggregation states of tau can dictate tau turnover via the proteasome.
The interaction between the UPS and tau
There is also evidence that tau can be degraded by the proteasome. It has been shown that proteasome inhibition in cell culture inhibits tau degradation [82, 96] . Similar results were obtained by another group showing that inhibitors against the trypsin-like and glutamyl-like activities almost completely blocked tau degradation [97] . More directly, these authors also showed that tau was degraded after incubation with the 20S proteasome in vitro [97] . Taken together these studies provide strong experimental evidence for the involvement of the UPS in tau turnover.
Particularly interesting are the findings highlighting the role of ubiquitination in tau turnover, especially in light of the data showing that alteration in the ubiquitin-dependent proteasomal degradation may be involved in neurodegeneration [98] . To this end, it has been shown that tau co-immunoprecipitates with the carboxy terminus of heat shock protein70-interacting protein (CHIP), an E3 ubiquitin ligase that ubiquitinates tau for degradation by the proteasome [99, 100] . These data were strongly supported by a recent work published by Dickey and colleagues showing that soluble phosphorylated tau accumulate in the brains of CHIP knockout mice [101] [76] .
Further supporting a role for the proteasome in the A␤ and tau interaction is the data showing an impairment of proteasome activity in the 3ϫTg-AD mice that correlates with an increase in A␤ oligomers [82] . Remarkably, accumulation of A␤ and tau was found after direct inhibition of proteasome activity in the 3ϫTg-AD mice [82] . Taken together, these data strongly suggest that the proteasome is a molecular link between A␤ and tau pathology (Fig. 2) 
